Clinical lung cancer

Biological Aging and Survival in Advanced Lung Cancer Patients Receiving Treatment

Updated

Abstract

Higher biological age (≥79.1 years) is independently associated with shorter overall survival in patients with advanced non-small cell lung cancer.

  • Chronological age (≥75 years) did not show the same predictive value for overall survival.
  • Biologically older patients in the immune checkpoint inhibitor cohort had significantly worse overall survival compared to biologically younger patients.
  • BioAge acceleration was identified as an independent prognostic factor for survival in the immune checkpoint inhibitor cohort.
  • No significant relationships were found between biological age, BioAge acceleration, or chronological age and the risk of immune-related adverse events.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Disclosure Yusuke Inoue has received honoraria from Chugai Pharma and AstraZeneca for speaking engagements (outside the submitted work). Kazuhiro Asada has received honoraria from Chugai Pharma, AstraZeneca for speaking engagements (outside the submitted work). The remaining authors declare that they have no conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free